跳至主要内容
临床试验/CTRI/2025/01/079094
CTRI/2025/01/079094尚未招募不适用

Effect of high protein diet on hepatic steatosis, inflammation and mitochondrial bioenergetics in patients with MAFLD : A randomized controlled trial

Indian Council of Medical Research1 个研究点 分布在 1 个国家目标入组 170 人开始时间: 2025年2月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
170
试验地点
1
主要终点
Improvement in Hepatic Steatosis

研究概览

简要总结

NAFLD is a growing problem in India. Its pathophysiology is complex, but focused on abnormal substrate handling due to mitochondrial dysfunction reflecting as metabolic inflexibility. Nutrition is the cornerstone of management. The ideal macronutrient distribution within a hypocaloric diet is not known yet. Evidence from experimental and a few human studies in obese, highlight the role of dietary proteins, independent of calorie restriction, in reducing hepatic steatosis by improving the cellular and systemic bioenergetics. Novelty: First study to assess the effect of high protein diet (HPD) in comparison to a standard protein diet (SPD) within a calorie restricted diet, on both the cellular and systemic bioenergetics in patients with NAFLD. Objectives: Aims to see the effect of HPD on hepatic steatosis, cellular and systemic bioenergetics, along with metabolic parameters in patients with NAFLD. Method: In this RCT, patients with MAFLD (n=140) with or without MS, would be randomized into HPD or SPD groups (i.e. 70 in each group), and parameters like hepatic steatosis (CAP by Transient elastography (FibroScan), cellular bioenergetics by oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) as measured using Seahorse Analyzer, and Indirect Calorimetry will be used to assess the fasting and postglucose challenge (Oral glucose tolerance test) REE and RQ. DEXA scan would be used to assess body composition apart from routine blood tests to assess features of Metabolic syndrome. The serum levels of GLP1, CKK, Ghrelin, FGF21, Adipokines like leptin and adiponectin, NADH/NAD ratio, insulin and glucagon would be measured. Outcome: A HPD is expected to improve hepatic steatosis, blunted fuel switching (RQ) and cellular bioenergetics (OCR) along with metabolic parameters in patients with NAFLD.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.Newly diagnosed treatment naive consenting adults with MAFLD (controlled attenuation parameter; CAP more than
  • Age 18-65 years.

排除标准

  • 1.Lean (BMI less than 23) 2.Individuals who had been hospitalized with complications of Diabetes mellitus, Chronic Kidney disease, Hypertension in the previous 6 months 3.Patients with viral hepatitis 4.Patients with significant alcohol consumption (regular consumption more than 10g per day for females and more than 20g/d in males), 5.Patients having chronic inflammatory bowel disease or any chronic and autoimmune diseases will be excluded 6.Pregnant & lactating women.

结局指标

主要结局

Improvement in Hepatic Steatosis

时间窗: 3 months

次要结局

  • 1.Changes in systemic bioenergetics(2.Changes in cellular bioenergetics)

研究者

申办方类型
Government funding agency
责任方
Principal Investigator
主要研究者

Kanika Jain

Institute of Liver and Biliary Sciences

研究点 (1)

Loading locations...

相似试验